Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 18/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 8/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 7/20 | 0.58 |
| ▸ | LGALS7; LGALS7B | P47929 | 7/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 4/20 | 0.57 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23374297 | 0.97 | LGALS3 (0.57) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL20868575 | 0.88 | LGALS3 (0.53) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL20868657 | 0.86 | LGALS3 (0.53) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL20869036 | 0.85 | LGALS3 (0.52) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL23374446 | 0.82 | LGALS3 (0.54) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL19580099 | 0.81 | LGALS3 (0.73) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL10067559 | 0.76 | LGALS3 (0.74) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL20911325 | 0.76 | SMYD3 (0.50) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL13385541 | 0.74 | LGALS3 (0.74) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 | |
| SCHEMBL10067561 | 0.74 | LGALS3 (1.00) | LGALS3LGALS9LGALS8LGALS7; LGALS7BLGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS9 5/4885LGALS8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.